All In Biotech

NDA 219007 · Teva

Weltruza

Olanzapine · Subcutaneous

Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

Oct 8, 2026

Approved uses

1

Original approval plus efficacy supplements

Registered trials

496

150 Phase 3, 32 recruiting

FAERS reports

69,868

63,963 serious, 9,096 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. WELTRUZA is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions ( 5.1 )] . WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. WELTRUZA is not approved for the treatment of patients with dementia-related psychosis. ( 5.1 , 8.5 )

What it is approved for

From the label in effect Oct 26, 2026.

WELTRUZA is indicated for the treatment of schizophrenia in adults. WELTRUZA is a long-acting atypical antipsychotic for subcutaneous injection indicated for the treatment of schizophrenia in adults. ( 1 )

Mechanism: The mechanism of action of olanzapine, in the listed indications, is unclear. However, the efficacy of olanzapine in schizophrenia could be mediated through a combination of dopamine and serotonin type 2 (5HT 2 ) antagonism.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • WELTRUZA · OLANZAPINE 531MG/VIAL · POWDER, SUBCUTANEOUS · Prescription
  • WELTRUZA · OLANZAPINE 318MG/VIAL · POWDER, SUBCUTANEOUS · Prescription
  • WELTRUZA · OLANZAPINE 425MG/VIAL · POWDER, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Olanzapine" as an intervention, any sponsor and status, largest first.

All 496 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective6,018
  • off label use4,340
  • toxicity to various agents4,064
  • drug interaction3,445
  • weight increased2,863
  • nausea2,799
  • somnolence2,774
  • condition aggravated2,404
  • fatigue2,383
  • vomiting2,382
  • suicide attempt2,350
  • overdose2,187

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004542
2005683
2006537
2007541
2008526
2009685
2010711
2011850
20121,324
20131,411
20141,742
20152,241
20162,617
20173,499
20184,896
20195,508
20205,181
20215,511
20226,270
20236,242
20246,577
20256,754
20265,020

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,214 on PubMed

Sponsor: Teva

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.